AbbVie Inc. (ABBV)
Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-31 |
| Earnings Call | 2025-10-31 |
| Avg EPS Estimate | 3.3553 |
| Low EPS Estimate | 3.32 |
| High EPS Estimate | 3.54 |
| Revenue | |
| Avg Revenue Forecast | 16,409,186,160 |
| Low Revenue Forecast | 16,235,000,000 |
| High Revenue Forecast | 17,008,000,000 |
ABBV Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $6,466,999,808 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 0 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $70,584,999,936 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
ABBV Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $28,500,000,768 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $0 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $0 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 71.20% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 35.77% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 4.00% | Net profit margin, which reflects overall profitability. |
ABBV Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 0.00% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $70,584,999,936 | Used together with cash and EBITDA to assess debt-paying ability. |
ABBV Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 9.10% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | -88.60% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for ABBV (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $216.77 | Latest stock trading price |
| Price Target (High) | $289 | Analyst highest expected price |
| Price Target (Low) | $184 | Analyst lowest expected price |
| Price Target (Average) | $240.39 | Average target price across analysts |
| Price Target (Median) | $242.5 | Median of target prices |
| Average Rating Score | 1.93 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 28 | Number of analysts providing estimates |
| Cash Holdings | $6,466,999,808 | Total cash held by the company |
| Cash per Share | $3.66 | Cash value per outstanding share |
| Total Debt | $70,584,999,936 | Company's total debt |
| Quick Ratio | 0 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 0 | Overall short-term liquidity |
| Debt/Equity Ratio | 0.00% | Leverage ratio: Debt / Equity |
| EBITDA | $28,500,000,768 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $59,643,998,208 | Total company revenue |
| Revenue per Share | $33.716 | Total revenue divided by shares outstanding |
| Gross Profit | 71.20% | Revenue minus cost of goods sold |
| Return on Assets | 0.00% | Net income / Total assets |
| Return on Equity | 0.00% | Net income / Shareholder equity |
| Earnings Growth (YoY) | -88.60% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 9.10% | Year-over-year revenue growth |
| Gross Margin | 71.20% | Gross profit / Total revenue |
| EBITDA Margin | 47.78% | EBITDA / Revenue |
| Operating Margin | 35.77% | Operating income / Revenue |
| Profit Margin | 4.00% | Net income / Revenue |
| Free Cash Flow | $0 | Cash left after capital expenditures |
| Operating Cash Flow | $0 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |